---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009609"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:18:52.719924+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCardia reports 2025 net loss $8.2M; cash $2.5M; regulatory milestones for CardiAMP anticipated

## Summary
- Net loss $8.2M (2025) vs $7.9M (2024); revenue $0; cash $2.5M at year-end.
- R&D expenses $5.0M (+$0.6M YoY) due to CardiAMP HF trial closeout and Japan regulatory work.
- CardiAMP HF II trial enrolling at 4 sites; Yale echo data showed reduced LV remodeling in treated patients.
- FDA Q-Sub on CardiAMP approval pathway expected Q1 2026; Japan PMDA formal consultation Q2 2026.
- Helix delivery system Pre-Submission accepted by FDA; meeting with CDRH/CBER scheduled Q2 2026.

## SEC filing metadata
- accession: 0001437749-26-009609
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774926009609/0001437749-26-009609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774926009609/bcda20260324_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009609
- JSON: https://secwatch.observer/filing/0001437749-26-009609.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009609.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.